Adcock Ingram recalls two batches of ARVs after packaging error
This article was originally published in Scrip
Executive Summary
Adcock Ingram, South Africa's largest pharmaceutical company, has recalled two of its antiretroviral products after investigations revealed tablets had been packed in the wrong cartons. Blisters of Batch 1J of Adco-Nevirapine tablets (200mg nevirapine, expiry January 2009) were found to have been packed in certain packs of Batch 1Z of Adco-Zidovudine tablet (300mg zidovudine, expiry November 2008). Adcock Ingram said blisters of the Adco-Nevirapine tablets were clearly labelled with the correct name and expiry date, but it has recalled both batches as a precautionary measure. The company has appealed to patients taking the medicine to consult their doctors and return products with the specific batch numbers immediately.
You may also be interested in...
How to leverage India: Five up-and-coming domestic players
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
Active Biotech appoints CSO
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed appoints new chief commercial officer
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).